Patent Application
20250051335
The present invention relates to TTBK enzyme inhibitors and their use for the treatment and/or prevention of tauopathies and/or TDP-43 diseases. Therefore, the invention may be comprised in the medical chemistry and pharmaceutical field.
Tau-tubulin kinases (TTBK) are a family of recently discovered serine/threonine and tyrosine kinases involved in the phosphorylation of important substrates such as tau, tubulin or TDP-43. Its two isoforms, TTBK1 and TTBK2, show different expression patterns and different participation in highly important physiological mechanisms, such as mitosis, ciliogenesis and neurotransmission.
It has recently been shown that TTBK are also responsible for the phosphorylation of TDP-43 (Liachko N F, et al. The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genet. 2014 Dec. 4; 10(12):e1004803), thus their phosphorylation activity has also linked them to the development of neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis. These neurodegenerative diseases are called tauopathies and TDP-43 diseases because they are associated with the pathological aggregation of tau and TDP-43 proteins, respectively, in the human brain.
In the following document: Nozal, A. Martinez, Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases, Eur J Med Chem 2019 Jan. 1; 161:39-47, the importance of the role played by the aforementioned TTBK kinases in neurodegenerative diseases such as Alzheimer's (AD), progressive supranuclear palsy, frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), etc, is already evident, proposing TTBK1 and TTBK2 as new targets for the treatment of said diseases and their selective inhibitors as potential effective drugs for their treatment, having been demonstrated very recently (Taylor L M, McMillan P J, Liachko N F, Strovas T J, Ghetti B, Bird T D, Keene C D, Kraemer B C. Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration. Mol Neurodegener. 2018 Feb. 6; 13(1):7) which are involved in neurodegenerative processes through not only the hyperphosphorylation of tau but also TDP-43.
Pursuant to the foregoing, inhibition of TTBK may be a promising approach for the treatment of neurodegenerative diseases such as those involving the tau protein and the TDP-43 protein, i.e., tauopathies and TDP-43 diseases.
Given that in the state of the art there are few known compounds that can act as inhibitors of said enzyme, the present invention proposes new compounds that act as inhibitors thereof, being useful for the treatment and/or prevention of neurodegenerative diseases where this enzyme is involved. It is, therefore, an alternative to or improvement on the compounds already known for the treatment of diseases of this type.
The present invention presents a family of compounds that have the ability to inhibit the TTBK1 and/or TTBK2 enzyme in micromolar order or lower, proving useful for the treatment and/or prevention of tauopathies and/or TDP-43 diseases.
In a first aspect, the present invention relates to a compound of formula (I)
or any of the isomers thereof or the pharmaceutically acceptable salts thereof
wherein:
The compounds of formula (I) act as inhibitors of the TTBK1 and/or TTBK2 enzymes, which are involved in tauopathies and TDP-43 diseases. These are, as indicated in the state of the art section, a class of neurodegenerative diseases associated with the pathological aggregation of tau protein or TDP-43, respectively, in the nervous system. They are, therefore, neurodegenerative diseases where tau-tubulin kinases (TTBK), such as TTBK1 and TTBK2, are involved.
Preferably, tauopathies are selected from the following list: Alzheimer's disease (AD), progressive supranuclear palsy, frontotemporal dementia (FTD), Pick's disease, Down's syndrome. More preferably, the tauopathy is selected from Alzheimer's disease (AD), and frontotemporal dementia (FTD) and, even more preferably, the tauopathy is Alzheimer's disease.
Preferably, the TDP-43 diseases are selected from the following list: amyotrophic lateral sclerosis (ALS), Alexander disease, limbic-predominant age-related TDP-43 encephalopathy (LATE), frontotemporal dementia (FTD) and Huntington's disease. More preferably, the TDP-43 disease is selected from frontotemporal dementia (FTD), limbic-predominant age-related TDP-43 encephalopathy (LATE) and amyotrophic lateral sclerosis (ALS) and, even more preferably, the TDP-43 disease is amyotrophic lateral sclerosis.
In a preferred embodiment of the compounds of the invention for use, at least two of R2, R3 and R4 are H. In another preferred embodiment of the compounds of the invention for use, two of R2, R3 and R4 are H and one of them is different from H. In another preferred embodiment of the compounds of the invention for use, R2, R3 and R4 are H.
In a preferred embodiment of the compounds of formula (I) for use, R1 is H.
In another preferred embodiment of the compounds of formula (I) for use, X is O.
In a more preferred embodiment, R1 is H and X is O. Even more preferably R1 is H, X is O and R2, R3 and R4 are independently selected from H, halogen, CN, NO2, NH2, C1-C3 alkyl, —(O)—C1-C3 alkyl.
In a preferred embodiment, R1 is H, X is O, R2 and R4 are H and R3 is selected from H, halogen, CF3, CN, NO2, NH2, C1-C3 alkyl, —(O)—C1-C3 alkyl, more preferably R3 is selected from H, halogen, CN, NO2, NH2, C1-C3 alkyl, —(O)— C1-C3 alkyl.
In a preferred embodiment, R1 is H, X is O, R2 and R3 are H and R4 is selected from halogen and —(O)—C1-C3 alkyl.
In a preferred embodiment, R1 is H, X is O, R3 and R4 are H and R2 is selected from halogen, CF3, —(O)—C1-C3 alkyl and C1-C3 alkyl, more preferably, R2 is selected from halogen, CF3, —(O)—C1-C3alkyl and alkyl C1-C3.
In another preferred embodiment, X is S. More preferably R1 is H, X is S. Even more preferably, R1 is H, X is S and R2, R3 and R4 are independently selected from H, NO2 and NH2.
In another preferred embodiment, X is CO. More preferably, X is CO and R1 is H. Even more preferably, X is CO, R1 is H and R2, R3 and R4 are independently selected from halogen and H.
In another embodiment of the present invention for use, R1 is NH2. More preferably, R1 is NH2 and X is O. Even more preferably, R1 is NH2, X is O and R2, R3 and R4 are independently selected from: H, halogen and CF3, at least one of them being different from H. Even more preferably, R1 is NH2, X is O, R4 is H and R2 and R3 are independently selected from: H, halogen and CF3, at least one of them being different from H.
In a more preferred embodiment of this first aspect, the invention relates to the compounds of formula (I) for use selected from the list comprising:
The structure of each of the compounds mentioned in the above list is indicated in the examples (See example 1).
A second aspect of the invention relates to a compound of formula (I)
or any of the isomers thereof or the pharmaceutically acceptable salts thereof, wherein R1, X, R2, R3 and R4 have the same meaning described above in the first aspect of the invention and wherein at least one of R2, R3 and R4 are H, provided that the compound is neither of the following two (I′) and (I″):
In a preferred embodiment, the invention relates to the compounds of formula (I) selected from the list comprising:
A third aspect of the invention relates to a compound of formula (I) or to any of the isomers thereof or the pharmaceutically acceptable salts thereof as defined in the first aspect of the invention provided that the compound is neither (I′) nor (I″), the formula of which has been indicated above, for use thereof as a medicinal product.
The invention also relates to a pharmaceutical composition comprising a compound of formula (I) or any of the isomers thereof or the pharmaceutically acceptable salts thereof as defined in the first aspect of the invention provided that the compound is neither (I′) nor (I″), the formula of which has been indicated above.
The term “pharmaceutical composition” refers to the composition that includes the compound of formula (I), except for (I′) and (I″), the isomers thereof or the pharmaceutically acceptable salts thereof, and at least one excipient, pharmaceutically acceptable adjuvant and/or carrier.
The term “excipients, adjuvants and/or carriers” refers to molecular entities or substances through which the active ingredient is administered. Said pharmaceutical excipients, adjuvants or carriers can be sterile liquids, like water and oils, including those of oil, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and similar oils, excipients, disintegrating agents, wetting agents or diluents. Pharmaceutically acceptable excipients and carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin.
The compounds of the present invention of formula (I) for use have the ability to cross the blood-brain barrier, as shown below in some of the examples. This represents an additional advantage of the compounds when using them in therapeutic treatments of diseases related to the central nervous system, such as tauopathies and TDP-43 diseases.
The compounds of the invention represented by formula (I) may be in crystalline form as free compounds or as solvates and both forms are intended to be within the scope of the present invention. The nature of the pharmaceutically acceptable solvate is not critical as long as it is pharmaceutically acceptable. In a particular embodiment, the solvate is a hydrate. The solvates can be obtained by conventional solvation methods known to those skilled in the art.
The compounds of formula (I) for therapeutic use are prepared in solid form or aqueous suspension, in a pharmaceutically acceptable diluent. These preparations can be administered by any appropriate route of administration, for which said preparation will be formulated in the pharmaceutical form suitable for the chosen route of administration. In a particular embodiment, the administration of the compound of formula (I) is carried out orally, topically, rectally or parenterally (including subcutaneously, intraperitoneally, intradermally, intramuscularly, intravenously, etc.).
Another aspect of the invention relates to a method for treating tauopathies and/or TDP-43 diseases comprising administering a therapeutically effective amount of a compound of formula (I) as described in the first aspect of the present invention to a subject.
A final aspect of the present invention refers to the use of a compound of formula (I) as described in the first aspect of the present invention for the preparation of a medicinal product for the treatment and/or prevention of tauopathies and/or TDP-43 diseases.
The compounds described in the present invention, the pharmaceutically acceptable salts thereof, solvates, as well as the pharmaceutical compositions containing them can be used together with other additional drugs in order to provide a combination therapy. Said additional drugs can make up part of the same pharmaceutical composition or, alternatively, they can be provided in the form of a separate composition for the administration thereof which is simultaneous or not to that of the pharmaceutical composition comprising a compound of formula (I), an isomer or a pharmaceutically acceptable salt thereof.
Unless indicated otherwise, the compounds of the invention also include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds that have said structure, with the exception of the substitution of hydrogen for deuterium or tritium, or the substitution of a carbon for a 13C or 14C enriched carbon or a 15N enriched nitrogen, are within the scope of this invention.
In the present invention, the term “C1-C3 alkyl” refers, in the present invention, to linear or branched hydrocarbon chain radicals, that have 1 to 3 carbon atoms and are joined to the rest of the molecule by a single bond, for example, propyl, ethyl, methyl, isopropyl, etc. When this substituent is present in the compounds of the invention, the “C1-C3 alkyl” is preferably methyl.
The term “halogen” refers to F, Cl, Br and I. When this substituent is present in the compounds of the invention, the halogen is preferably Cl.
The expression “treatment and/or prevention” as used herein, unless indicated otherwise, means to revert, alleviate, inhibit the progress of, or prevent the disorder or condition to which it applies in such terms, one or more symptoms of such disorder or condition.
Throughout the description and the claims, the word “comprises” and its variants are not intended to exclude other technical features, additives, components or steps. For those skilled in the art, other objects, advantages and features of the invention may be partially deduced from both the description and the embodiment of the invention. The following examples are provided by way of illustration and are not intended to limit the present invention.
Next, the invention will be illustrated by means of assays carried out by the inventors which demonstrate the effectiveness of the product of the invention.
General methodology: 1 equivalent (250 mg, 1.63 mmol) of 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine or 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 1 equivalent (1.63 mmol) of the corresponding aniline (both reagents commercially available from SigmaAldrich or Fluorochem) are dissolved in 2 ml of tetrahydrofuran. The crude mixture is stirred under microwave radiation at 100° C. until the reaction is complete. Then, the crude mixture is extracted with 20 ml of ethyl acetate and washed with saturated NaHCO3 and NaCl solutions, the organic phases are combined and dried with MgSO4, they are filtered and the solvent is removed under reduced pressure. The resulting crude mixture is purified using column chromatography using an appropriate mixture of DCM and MeOH as eluents.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-phenoxyaniline
m.p.: 250-251° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.75 (s, 1H), 9.34 (s, 1H), 8.26 (s, 1H), 7.89 (d, J=9.0 Hz, 2H), 7.37 (dd, J=8.6, 7.3 Hz, 2H), 7.23 (dd, J=3.5, 2.3 Hz, 1H), 7.13-6.96 (m, 5H), 6.77 (dd, J=3.5, 1.9 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6) δ (ppm) 157.6, 153.5, 150.8, 150.75, 150.7, 136.3, 129.9, 122.7, 122.1, 122.0, 119.4, 117.6, 103.5, 98.7. Elemental analysis C18H14N4O Calculated % C 71.51, % H 7.67, % N 18.53 Found % C 71.04, % H 4.70, % N 18.38.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(4-chlorophenoxy)aniline
m.p.: 250-251° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.77 (s, 1H), 9.36 (s, 1H), 8.26 (s, 1H), 7.92 (d, J=9.0 Hz, 2H), 7.41 (d, J=9.0 Hz, 2H), 7.24 (dd, J=3.4, 2.3 Hz, 1H), 7.06 (d, J=9.0 Hz, 2H), 7.00 (d, J=9.0 Hz, 2H), 6.77 (dd, J=3.5, 1.9 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6) δ 156.7, 153.4, 150.8, 150.7, 150.2, 136.8, 129.7, 126.4, 122.1, 121.9, 119.7, 119.2, 103.5, 98.7. C18H13ClN4O Theoretical % C 64.20, % H 3.89, % N 16.64 Experimental % C 65.15, % H 3.96, % N 16.69.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(4-fluorophenoxy)aniline m.p.: 227-228° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.75 (s, 1H), 9.33 (s, 1H), 8.25 (s, 1H), 7.88 (d, J=9.0 Hz, 2H), 7.26-7.15 (m, 3H), 7.08-6.95 (m, 4H), 6.76 (dd, J=3.5, 1.9 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 159.4 (d, J=238.1 Hz, 153.6 (d, J=2.3 Hz), 153.5, 151.3, 150.8, 136.3, 122.1, 122.0, 119.6 (d, J=8.4 Hz), 119.0, 116.4 (d, J=23.3 Hz), 103.5, 98.7. C18H13FN4O Theoretical % C 67.49, % H 4.09, % N 17.49 Experimental % C 67.09, % H 4.09, % N 17.38.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(4-cyanophenoxy)aniline
m.p.: 259-260° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.77 (s, 1H), 9.41 (s, 1H), 8.28 (s, 1H), 7.99 (d, J=9.0 Hz, 2H), 7.83 (d, J=8.9 Hz, 2H), 7.25 (dd, J=3.5, 2.3 Hz, 1H), 7.15 (d, J=9.0 Hz, 2H), 7.09 (d, J=8.9 Hz, 2H), 6.79 (dd, J=3.5, 1.8 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 161.9, 153.3, 150.8, 150.7, 148.4, 137.8, 134.6, 122.2, 121.8, 120.7, 118.8, 117.3, 104.5, 103.6, 98.7. C19H13N5O Theoretical % C 69.71, % H 4.00, % N 21.39 Experimental % C 69.33, % H 4.15, % N 21.01.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(4-methoxyphenoxy)aniline.
m.p.: 202-203° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.74 (s, 1H), 9.30 (s, 1H), 8.25 (s, 1H), 7.84 (d, J=9.0 Hz, 2H), 7.23 (dd, J=3.5, 2.3 Hz, 1H), 7.04-6.94 (m, 6H), 6.76 (dd, J=3.1, 1.9 Hz, 1H), 3.76 (s, 3H). 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 155.2, 153.5, 152.4, 150.8, 150.7, 150.4, 135.5, 122.0, 121.9, 119.8, 118.0, 115.0, 103.4, 98.7, 55.4. C19H16N4O2 Theoretical % C 68.66, % H 4.85, % N 16.86 Experimental % C 67.97, % H 4.91, % N 16.64.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(4-trifluoromethylphenoxy)aniline
m.p.: 233-234° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.77 (s, 1H), 9.40 (s, 1H), 8.28 (s, 1H), 7.98 (d, J=9.0 Hz, 2H), 7.72 (d, J=8.7 Hz, 2H), 7.24 (dd, J=3.5, 2.3 Hz, 1H), 7.14 (t, J=9.1 Hz, 4H), 6.79 (dd, J=3.5, 1.9 Hz, 1H). 13C-MNR (75 MHz, DMSO-d6): δ (ppm) 162.1, 154.3, 151.7, 151.6, 149.9, 138.4, 128.3 (q, J=3.6 Hz), 125.2 (q, J=271.7 Hz), 123.6 (q, J=32.1 Hz), 123.1, 122.7, 121.4, 118.0, 104.5, 99.6. C19H13F3N4O Theoretical % C 61.62, % H 3.54, % N 15.13 Experimental % C 61.55, % H 3.51, % N 15.04.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(4-bromophenoxy)aniline
m.p.: 257-258° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.75 (s, 1H), 9.35 (s, 1H), 8.27 (s, 1H), 7.93 (d, J=9.0 Hz, 2H), 7.54 (d, J=9.0 Hz, 2H), 7.24 (dd, J=3.5, 2.3 Hz, 1H), 7.08 (d, J=9.0 Hz, 2H), 6.96 (d, J=8.9 Hz, 2H), 6.78 (dd, J=3.5, 1.9 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6) δ 157.7, 153.9, 151.3, 151.2, 150.6, 137.3, 133.1, 122.6, 122.4, 120.2, 120.1, 114.7, 104.0, 99.2. C18H13BrN4O Theoretical % C 56.71, % H 3.44, % N 14.70 Experimental % C 56.21, % H 3.51, % N 14.43.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(4-nitrophenoxy)aniline
m.p.: 270° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.86 (s, 1H), 9.63 (s, 1H), 8.35-8.16 (m, 3H), 8.00 (d, J=9.0 Hz, 2H), 7.29-7.24 (m, 1H), 7.20 (d, J=9.0 Hz, 2H), 7.14 (d, J=9.3 Hz, 2H), 6.84 (dd, J=3.5, 1.9 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6) δ 163.6, 153.1, 150.5, 150.1, 148.7, 142.0, 137.7, 126.2, 122.5, 122.3, 120.9, 116.9, 103.6, 99.1. ESI calculated for C18H13N5O3 [M+H]+ 348.1091 found 348.1088.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(4-aminophenoxy)aniline
m.p.: 242-243° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.68 (s, 1H), 9.21 (s, 1H), 8.21 (s, 1H), 7.75 (d, J=9.0 Hz, 2H), 7.19 (dd, J=3.5, 2.3 Hz, 1H), 6.87 (d, J=9.0 Hz, 2H), 6.76 (d, J=8.8 Hz, 2H), 6.71 (dd, J=3.5, 1.9 Hz, 1H), 6.58 (d, J=8.8 Hz, 2H), 4.92 (s, 2H). 13C-NMR (75 MHz, DMSO-d6) δ 153.74, 153.64, 150.8, 150.7, 146.5, 145.1, 134.7, 122.1, 121.9, 120.3, 117.0, 114.8, 103.3, 98.7. ESI calculated for C18H15N5O [M+H]+ 318.1349 found 318.1348.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(4-methylphenoxy)aniline
m.p.: 229° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.72 (s, 1H), 9.29 (s, 1H), 8.24 (s, 1H), 7.85 (d, J=9.0 Hz, 2H), 7.22 (dd, J=3.5, 2.4 Hz, 1H), 7.17 (dd, J=8.8, 0.7 Hz, 2H), 6.99 (d, J=9 Hz, 2H), 6.89 (d, J=8.5 Hz, 2H), 6.75 (dd, J=3.5, 1.9 Hz, 1H), 2.28 (s, 3H). 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 155.2, 153.5, 151.5, 150.8 (C-2, 4), 136.0, 131.9, 130.3, 122.03, 121.98, 118.9, 117.9, 103.5, 98.7, 20.2. C19H16N4O Theoretical % C 72.13, % H 5.10, % N 17.71 Experimental % C 71.84, % H 5.15, % N 17.96.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(3-methylphenoxy)aniline
m.p.: 212-213° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.73 (s, 1H), 9.31 (s, 1H), 8.25 (s, 1H), 7.88 (d, J=9.0 Hz, 2H), 7.28-7.20 (m, 2H), 7.02 (d, J=9.0 Hz, 2H), 6.91 (ddt, J=7.5, 1.7, 0.8 Hz, 1H), 6.82-6.78 (m, 3H), 2.28 (s, 3H). 13C-NMR (75 MHz, DMSO-d6) δ (ppm) 157.7, 153.5, 150.9, 150.79, 150.76, 139.6, 136.3, 129.6, 123.5, 122.1, 121.9, 119.4, 118.1, 114.7, 103.5, 98.7, 21.0. ESI calculated for C19H16N4O [M+H]+ 317.1397 found 317.1393.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(3-chlorophenoxy)aniline
m.p.: 224-225° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.79 (s, 1H), 9.39 (s, 1H), 8.29 (s, 1H), 7.96 (d, J=9.0 Hz, 2H), 7.41 (t, J=8.1 Hz, 1H), 7.26 (dd, J=3.5, 2.2 Hz, 1H), 7.17 (ddd, J=8.0, 2.0, 0.9 Hz, 1H), 7.12 (d, J=9.0 Hz, 2H), 7.03 (t, J=2.2 Hz, 1H), 6.97 (ddd, J=8.3, 2.3, 0.8 Hz, 1H), 6.80 (dd, J=3.5, 1.8 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 158.9, 153.4, 150.8, 150.8, 149.7, 137.1, 133.9, 131.4, 122.5, 122.2, 121.9, 120.0, 117.2, 116.0, 103.5, 98.7. C18H13ClN4O Theoretical % C 64.20, % H 3.89, % N 16.64 Experimental % C 64.06, % H 3.91, % N 16.75.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(3-trifluoromethylphenoxy)aniline
m.p.: 176-177° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.75 (s, 1H), 9.37 (s, 1H), 8.27 (s, 1H), 7.96 (d, J=9.0 Hz, 2H), 7.61 (t, J=7.8 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 7.32-7.19 (m, 3H), 7.13 (d, J=8.9 Hz, 2H), 6.78 (dd, J=3.5, 1.9 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 158.8, 153.8, 151.2, 151.1, 149.9, 137.6, 131.6, 130.95 (q, J=32 Hz), 127.7 (d, J=272.5 Hz), 122.5, 122.3, 121.5, 120.5, 119.5 (d, J=3.9 Hz), 113.9 (d, J=4.0 Hz), 103.9, 99.1. C19H13F3N4O Theoretical % C 61.62, % H 3.54, % N 15.13 Experimental % C 61.60, % H 3.47, % N 15.22.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(2-chlorophenoxy)aniline
m.p.: 215° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.73 (s, 1H), 9.33 (s, 1H), 8.25 (s, 1H), 7.89 (d, J=9.0 Hz, 2H), 7.58 (dd, J=8.0, 1.6 Hz, 1H), 7.34 (ddd, J=8.2, 7.4, 1.6 Hz, 1H), 7.22 (dd, J=3.5, 2.4 Hz, 1H), 7.17 (ddd, J=8.0, 7.4, 1.5 Hz, 1H), 7.05-6.95 (m, 3H), 6.76 (dd, J=3.5, 1.9 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6):δ (ppm) 153.5, 152.6, 150.80, 150.74, 150.71, 136.5, 130.6, 128.7, 124.6, 123.8, 122.1, 122.0, 119.8, 118.4, 103.5, 98.7. C18H13ClN4O Theoretical % C 64.20, % H 3.89, % N 16.64 Experimental % C 64.11, % H 3.96, % N 16.63.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(2-methoxyphenoxy)aniline
m.p.: 214-215° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.69 (s, 1H), 9.23 (s, 1H), 8.21 (s, 1H), 7.76 (d, J=9.0 Hz, 2H), 7.20 (dd, J=3.5, 2.3 Hz, 1H), 7.18-7.14 (m, 2H), 7.02-6.92 (m, 2H), 6.86 (d, J=9.1 Hz, 2H), 6.71 (dd, J=3.5, 1.9 Hz, 1H), 3.77 (s, 3H). 13C-NMR (75 MHz, DMSO-d6) δ (ppm) 153.6, 152.6, 151.1, 150.8, 150.7, 144.6, 135.0, 124.9, 122.1, 121.9, 121.0, 120.7, 116.7, 113.3, 103.3, 98.7, 55.6. C19H16N4O2 Theoretical % C 68.66, % H 4.85, % N 16.96 Experimental % C 68.006, % H 4.82, % N 16.97.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(2,4-dichlorophenoxy)aniline
m.p.: 252-253° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.72 (s, 1H), 9.37 (s, 1H), 8.24 (s, 1H), 7.89 (d, J=9.1 Hz, 2H), 7.72 (d, J=2.5 Hz, 1H), 7.39 (dd, J=8.8, 2.6 Hz, 1H), 7.22 (dd, J=3.5, 2.3 Hz, 1H), 7.02 (dd, J=8.9, 2.1 Hz, 3H), 6.75 (dd, J=3.5, 1.9 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6) δ (ppm) 153.6, 152.0, 150.9, 150.5, 136.9, 130.1, 128.8, 127.7, 124.9, 122.4, 122.2, 120.9, 118.8, 103.7, 98.9. C18H12Cl2N4O Theoretical % C 58.24, % H 3.26, % N 15.09 Experimental % C 58.13, % H 3.33, % N 15.17.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-(3-methoxyphenoxy)aniline
m.p.: 210-211° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.73 (s, 1H), 9.32 (s, 1H), 8.25 (s, 1H), 7.89 (d, J=9.0 Hz, 2H), 7.31-7.20 (m, 2H), 7.05 (d, J=9.0 Hz, 2H), 6.76 (dd, J=3.5, 1.8 Hz, 1H), 6.67 (ddd, J=8.3, 2.4, 0.9 Hz, 1H), 6.59-6.48 (m, 2H), 3.73 (s, 3H), 13C-NMR (75 MHz, DMSO-d6):δ (ppm) 160.6, 158.9, 153.5, 150.80, 150.75, 150.5, 136.5, 130.4, 122.1, 121.9, 119.6, 109.5, 108.4, 103.7, 103.5, 98.7, 55.2, ESI calculated for C19H16N4O2 [M+H]+ 333.1346 found 333.1342.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine and 4-(4-trifluoromethylphenoxy)aniline
m.p.: 201-202° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 10.85 (s, 1H), 8.99 (s, 1H), 8.03 (d, J=9.0 Hz, 2H), 7.72 (d, J=9.0 Hz, 2H), 7.11 (dd, J=9.0, 0.8 Hz, 2H), 7.07 (d, J=9.0 Hz, 2H), 6.77 (dd, J=3.5, 2.2 Hz, 1H), 6.55 (dd, J=3.5, 1.9 Hz, 1H), 5.72 (s, 2H). 13C-NMR (75 MHz, DMSO-d6) δ (ppm) 161.3, 159.4, 153.9, 153.5, 148.5, 138.2, 127.4 (q, J=3.7 Hz), 124.4 (d, J=271.1 Hz), 122.7 (d, J=32 Hz), 121.2, 120.4, 117.9, 117.1, 108.5, 98.8, 96.9. ESI calculated for C19H14F3N5O [M+H]+ 386.1223 found 386.1220.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine and 4-(3-trifluoromethylphenoxy)aniline
m.p.: 179-180° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 10.84 (s, 1H), 8.98 (s, 1H), 8.02 (d, J=9.1 Hz, 2H), 7.60 (t, J=7.9 Hz, 1H), 7.44 (ddt, J=7.7, 1.7, 0.9 Hz, 1H), 7.32-7.20 (m, 2H), 7.06 (d, J=9.0 Hz, 2H), 6.76 (dd, J=3.5, 2.2 Hz, 1H), 6.54 (dd, J=3.5, 2.0 Hz, 1H), 5.72 (s, 2H), 13C-NMR (75 MHz, DMSO-d6) δ 159.4, 158.6, 153.9, 153.5, 148.9, 138.0, 131.3, 130.6 (d, J=31.9 Hz), 123.8 (d, J=272.5 Hz), 121.3, 121.1, 120.0, 119.0 (d, J=4.1 Hz), 117.9, 113.4 (d, J=4.0 Hz), 98.8, 96.9, ESI calculated for C19H14F3N5O [M+H]+ 386.1223 found 386.1219.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine and 4-(4-chlorophenoxy)aniline
m.p.: 232-233° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 10.83 (s, 1H), 8.94 (s, 1H), 7.98 (d, J=9.1 Hz, 2H), 7.41 (d, J=9.0 Hz, 2H), 6.99 (m, 4H), 6.76 (dd, J=3.5, 2.1 Hz, 1H), 6.53 (dd, J=3.5, 1.9 Hz, 1H), 5.70 (s, 2H). 13C-NMR (75 MHz, DMSO-d6) δ 159.4, 156.8, 154.0, 153.5, 149.7, 137.5, 129.7, 126.3, 121.3, 119.5, 119.1, 117.8, 98.8, 96.9. ESI calculated for C18H14ClN5O [M+H]+ 352.0960 found 352.0956.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine and 4-(3-chlorophenoxy)aniline
m.p.: 177-178° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 10.84 (s, 1H), 8.97 (s, 1H), 8.00 (d, J=9.0 Hz, 2H), 7.39 (t, J=8.1 Hz, 1H), 7.14 (ddd, J=8.0, 2.0, 0.9 Hz, 1H) 7.03 (d, J=9.0 Hz, 2H) 6.99 (t, J=2.2 Hz, 1H), 6.94 (ddd, J=8.3, 2.4, 0.9 Hz, 1H), 6.76 (dd, J=3.5, 2.2 Hz, 1H), 6.54 (dd, J=3.5, 1.9 Hz, 1H), 5.71 (s, 2H). 13C-NMR (75 MHz, DMSO-d6) δ (ppm) 159.4, 159.1, 153.9, 153.5, 149.1, 137.8, 133.9, 131.3, 122.5, 121.3, 119.9, 117.8, 117.1, 116.0, 98.8, 96.9. ESI calculated for C18H14ClN5O [M+H]+ 352.0960 found 352.0955.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-((4-nitrophenyl)thio)aniline
m.p.: 265-266° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 12.46 (s, 1H), 10.72 (s, 1H), 8.43 (s, 1H), 8.17 (d, J=8.6 Hz, 2H), 8.00 (d, J=8.1 Hz, 2H), 7.67 (d, J=8.2 Hz, 2H), 7.44 (t, J=2.6 Hz, 1H), 7.33 (d, J=8.6 Hz, 2H), 7.03 (t, J=2.4 Hz, 1H). 13C-MNR (75 MHz, DMSO-d6) δ 151.7, 148.3, 147.6, 146.6, 144.9, 139.9, 135.7, 126.4, 124.3, 124.1, 123.7, 123.5, 103.7, 100.7. C18H13N5O2S Theoretical % C 59.49, % H 3.61, % N 19.27% S 8.82 Experimental % C 59.26, % H 3.70, % N 19.37% S 8.95.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4,4′-thiodianiline
m.p.: 200-201° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.73 (s, 1H), 9.30 (s, 1H), 8.24 (s, 1H), 7.80 (d, J=8.8 Hz, 2H), 7.23 (dd, J=3.5, 2.3 Hz, 1H), 7.22 (dd, J=3.5, 2.3 Hz, 1H), 7.14 (dd, J=16.7, 8.6 Hz, 4H), 6.84 (dd, J=3.5, 1.9 Hz, 1H), 6.61 (d, J=8.5 Hz, 2H), 5.48 (s, 1H). 13C-NMR (75 MHz, DMSO-d6) δ 153.3, 150.8, 150.6, 149.3, 138.5, 135.0, 131.3, 128.2, 122.1, 120.9, 117.1, 114.7, 103.6, 98.7. C18H15N5S Theoretical % C 59.49, % H 3.61, % N 19.27% S 8.82 Experimental % C 59.26, % H 3.70, % N 19.37% S 8.95.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 4-benzyloxyaniline
m.p.: 238-239° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.66 (s, 1H), 9.15 (s, 1H), 8.20 (s, 1H), 7.71 (d, J=9.1 Hz, 2H), 7.50-7.29 (m, 5H), 7.18 (dd, J=3.5, 2.4 Hz, 1H), 7.00 (d, J=9.1 Hz, 2H), 6.67 (dd, J=3.5, 1.9 Hz, 1H), 5.09 (s, 2H). 13C-NMR (75 MHz, DMSO-d6):δ (ppm) 153.80, 153.76, 150.9, 150.7, 137.3, 133.5, 128.4, 127.74, 127.66, 122.3, 122.0, 114.7, 103.2, 98.7, 69.4. ESI calculated for C19H16N4O [M+H]+ 317.1397 found 317.1395.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and (4-aminophenyl)phenylmethanone
m.p.: 247-248° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.91 (s, 1H), 9.76 (s, 1H), 8.38 (s, 1H), 8.16 (d, J=8.9 Hz 2H), 7.79 (d, J=8.8 Hz, 2H), 7.77-7.53 (m, 5H), 7.32 (dd, J=3.5, 2.3 Hz, 1H), 6.89 (dd, J=3.5, 1.9 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 194.4, 152.8, 151.2, 150.5, 145.1, 137.9, 132.0, 131.1, 129.6, 129.3, 128.4, 123.0, 118.6, 104.4, 98.7. ESI calculated for C19H14N4O [M+H]+ 315.1240 found 315.1238.
Reagents: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and (4-aminophenyl)(4′-fluorophenyl)methanone
m.p.: 275-276° C. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.89 (s, 1H), 9.75 (s, 1H), 8.38 (s, 1H), 8.16 (d, J=8.9 Hz, 2H), 7.93-7.72 (m, 4H), 7.39 (t, J=8.9 Hz, 2H), 7.32 (dd, J=3.5, 2.3 Hz, 1H), 6.88 (dd, J=3.5, 2.3, 1H). 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 193.1, 164.3 (d, J=250.3 Hz, 152.9, 151.2, 150.5, 145.2, 134.5 (d, J=3.2 Hz), 132.2 (d, J=9.2 Hz), 131.1, 129.5, 123.0, 118.7, 115.5 (d, J=22.0 Hz), 104.4, 98.8. C19H13FN4O Theoretical % C 68.67, % H 3.94, % N 16.86 Experimental % C 68.32, % H 3.90, % N 16.72.
A buffer solution containing the recombinant human enzyme TTBK1 (1-1321) or TTBK2(1-450) (5-20 mU) and 50 mM Tris at pH 7.5, 0.1 mM EGTA, 0.1% p-mercaptoethanol, 1 mg/ml BSA, 10 mM DTT, is tested against the peptide RRKDLHDDEEDEAMSITA (SEQ ID NO: 1) in a final volume of 25.5 μl. The final reaction mixture contains the peptide at a concentration of 0.3 mM, 10 mM magnesium acetate and 0.005 mM [33P-γ-ATP](50-1000 cpm/pmol). The reaction mixture is incubated for 30 minutes at room temperature and the reaction is stopped after the addition of 5 μl of orthophosphoric acid. The mixture is placed on P81 Unifilter plates and washed with 50 mM orthophosphoric acid for data reading (see Table 1).
The prediction of crossing the blood-brain barrier (BBB) was carried out using the PAMPA (Parallel Artificial Membrane Permeability Assay) methodology (Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem. 1998; 41(7):1007-1010; Di L, Kerns E H, Fan K, McConnell O J, Carter G T. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem. 2003; 38(3):223-232). This technique consists of an artificial system of parallel plates separated by a membrane covered with porcine brain lipid that emulates the BBB. To validate the study, 10 commercial drugs approved by the FDA were used, the permeability of which in humans is known: enoxacin, hydrocortisone, desipramine, caffeine, ofloxacin, piroxicam, testosterone, promazine, verapamil and atenolol (Di L, Kerns E H, Fan K, McConnell O J, Carter G T. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem. 2003; 38(3):223-232). The study compounds and controls (1-2 mg) were dissolved in 5 ml of the buffer of the assay: phosphate buffered saline (PBS, pH 7.4) and ethanol (EtOH) in a 70:30 ratio. Next, they were filtered and subsequently scanned with the Varioskan™ ultraviolet (UV) reader (Thermo Fisher) from wavelength 220 to 400 nm, obtaining as a result a spectrum for each compound in which the wavelengths at which each one of them absorbs were identified.
Once the initial concentration of each compound has been determined by the absorbance obtained at the established wavelengths (initial absorbance), 180 μl of each sample was added to the 96-well donor plate, the bottom of which is a semipermeable membrane that was previously covered with 5 μl of porcine brain lipid dissolved in dodecane (20 mg/ml). The 96-well acceptor plate was filled with 180 μl/well of the buffer of the assay. Next, the donor plate was superimposed on the acceptor plate forming a “sandwich” for 2.5 hours at room temperature in a humid atmosphere. After the incubation period, the donor plate was removed and the absorbance of the solutions of the acceptor plate was read at the wavelengths previously established, calculating the effective permeability (Ep) of each compound based on the correlation established between the experimental Ep and the Ep described in the bibliography of the 10 control drugs according to the protocol described in the literature mentioned above (Table 1). In this way, the probability of crossing the BBB of each study compound is predicted, being high (CNS+), low (CNS−) or uncertain (CNS+/CNS−) (Table 1). Each sample was analysed from 3 to 5 wavelengths, in triplicate, and in 2 independent assays. The results are shown as the average of the 2 trials with their standard deviation value.
Human neuroblastoma cells (SH—SYSY) are seeded in 96-well plates at a density of 60,000 cells/well. When they are at confluence, they are exposed to 40 μM of ethacrynic acid (EA), having been pre-treated one hour before with the study compounds and controls dissolved in DMSO at the determined concentration (5 μM). Cell viability was evaluated after an incubation period of 24 hours from the addition of the EA using the MTT assay (Morgan D M. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol Biol. 1998; 79:179-183) (
The evaluation of the neuroprotective effect at the protein expression level was analysed using the Western blot technique (
Human neuroblastoma cells (SH-SY5Y) are seeded in 96-well plates at a density of 15,000 cells/well. When they are at confluence, they are exposed to 30 nM of okadaic acid (OA), having been pre-treated one hour before with the study compounds and controls dissolved in DMSO at the determined concentration (1 μM). Okadaic acid is a phosphatase inhibitor and its cellular toxicity is associated with an increase in hyperphosphorylation of the tau protein (Harris K. A., Oyler G A, Doolittle G M, Vincent I, Lehman R A, Kincaid R L, Billingsley M L. Okadaic acid induces hyperphosphorylated forms of tau protein in human brain slices. Ann Neurol. 1993 January; 33(1):77-87). The neuroprotection carried out by the compounds was evaluated after an incubation period of 24 hours from the addition of the OA using the MTT assay (Morgan D M. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol Biol. 1998; 79:179-183) (
TTBK1 inhibitors, permeable to the blood-brain barrier and capable of reducing the phosphorylation of tau and TDP-43 in cell models, they may be good drug candidates for the treatment of diseases of the central nervous system that cause hyperphosphorylation of tau and TDP-43 proteins. To that end, the inhibitors described in the present patent could be used for the treatment and/or prevention of pathologies such as Alzheimer's disease, amyotrophic lateral sclerosis and frontotemporal dementia, in which half of the patients show alterations in tau and the other half in TDP-43, among other neurodegenerative pathologies.
| Number | Date | Country | Kind |
|---|---|---|---|
| P202130653 | Jul 2021 | ES | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/ES2022/070436 | 7/7/2022 | WO |
